U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT07452250) titled 'Ferumoxytol-enhanced Magnetic Resonance Venography in Patients With Venous Diseases' on Feb. 28.
Brief Summary: The purpose of this single-center, prospective, evaluator-blinded study is to establish and optimize the imaging protocol for ferumoxytol-enhanced magnetic resonance venography (Fe-MRV) in patients with venous system diseases.
Current gadolinium-based contrast agents used in MRI have limitations, including short circulation half-lives and potential risks for patients with renal impairment. Ferumoxytol, a superparamagnetic iron oxide nanoparticle, offers a longer imaging window and no renal toxicity, making it a promising ...